Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
05:39:25 EDT Wed 25 Jun 2025
Enter Symbol
or Name
USA
CA



Q:FATE - FATE THERAPEUTICS - https://www.fatetherapeutics.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
FATE - Q0.11.06·1.300.41.17+0.032.61,323.81,4014,4891.16  1.23  1.165.91  0.6611Jun 24Jun 1115 min RT 2¢

Recent Trades - Last 10 of 4489
Time ETExPriceChangeVolume
     
     
     
     
     
     
     
     
     
     

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-06-11 09:00U:FATENews ReleaseFate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress
2025-05-30 16:30U:FATENews ReleaseFate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors
2025-05-28 17:54U:FATENews ReleaseFate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress
2025-05-13 16:01U:FATENews ReleaseFate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates
2025-05-02 16:01U:FATENews ReleaseFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2025-04-29 09:26U:FATENews ReleaseFate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting
2025-04-14 08:00U:FATENews ReleaseFate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE)
2025-04-02 16:01U:FATENews ReleaseFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2025-03-05 16:01U:FATENews ReleaseFate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates
2025-03-04 16:01U:FATENews ReleaseFate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
2025-02-14 16:01U:FATENews ReleaseFate Therapeutics to Present at Upcoming Investor Conferences
2025-02-04 16:01U:FATENews ReleaseFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2025-01-03 16:01U:FATENews ReleaseFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2024-12-09 16:01U:FATENews ReleaseFate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus
2024-12-03 16:01U:FATENews ReleaseFate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
2024-11-29 13:05U:FATENews ReleaseFate Therapeutics Announces Leadership Transition
2024-11-26 16:01U:FATENews ReleaseFate Therapeutics to Present at Upcoming December Investor Conferences
2024-11-18 08:05U:FATENews ReleaseFate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence
2024-11-18 08:00U:FATENews ReleaseFate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence
2024-11-12 16:01U:FATENews ReleaseFate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates